Login to Your Account

Aerie regains heights after solid Rocket 2 data with IOP-lowering drops

By Jennifer Boggs
Managing Editor

Thursday, September 17, 2015

Aerie Pharmaceuticals Inc. returned to its previous heights following positive results from the second phase III trial of its triple-action eye drop Rhopressa, which hit its endpoints in lowering IOP in patients with glaucoma or ocular hypertension.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription